Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk that is approved by the U.S. Food ...

Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults with obesity, both with and without type 2 diabetes, but did not increase the ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist ...

Wegovy HD will be available in April across all distribution channels, including retail pharmacies and select telehealth providers. The Food and Drug Administration (FDA) has approved Wegovy ® HD ...

The first generic weight-loss GLP-1 injection Sevmia was recently approved by Health Canada. Here’s what you need to know.

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight reduction under the FDA’s National Priority Voucher framework. STEP UP (n=1407) ...

A higher 7.2 mg dose of semaglutide led to significantly greater weight loss compared with placebo in adults with obesity, with or without type 2 diabetes. Participants across two randomized trials ...